(18MF) Amundi Leveraged MSCI USA - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: FR0010755611

Leveraged, Equity, Inverse, Trading, Index, MSCI, USA

Description: 18MF Amundi Leveraged MSCI USA

The Amundi ETF Leveraged MSCI USA Daily UCITS ETF is an exchange-traded fund listed on XETRA, providing investors with 2x leveraged exposure to the MSCI USA Index. This ETF is designed for traders seeking to capitalize on short-term movements in the US equity market.

From a technical analysis perspective, the ETFs price action indicates a potential bullish trend. The short-term Simple Moving Average (SMA20) is above the medium-term SMA50, suggesting an upward momentum. However, the long-term SMA200 is still above the current price, indicating a potential resistance level. The Average True Range (ATR) is relatively low, indicating a stable volatility environment.

Fundamentally, the ETFs Assets Under Management (AUM) stand at 501.84M EUR, indicating a moderate level of investor interest. As a leveraged ETF, its essential to consider the underlying indexs performance and the overall market conditions. The MSCI USA Index is a widely followed benchmark, and its performance is closely tied to the US economy and market sentiment.

Using a combination of technical and fundamental analysis, a potential forecast for the ETF could be as follows: if the MSCI USA Index continues to trend upwards, the ETFs price is likely to follow, potentially breaking above the SMA200 resistance level. However, if the index experiences a downturn, the ETFs leveraged nature will amplify the losses. Therefore, traders should closely monitor the underlying index and adjust their positions accordingly. A potential trading strategy could involve setting a stop-loss order below the SMA50 and scaling into positions as the price breaks above the SMA200.

Its also worth noting that leveraged ETFs are designed for short-term trading and may not be suitable for long-term investors due to the potential for significant losses if the market moves against the funds position. As such, traders should have a clear understanding of the ETFs mechanics and risks before investing.

Additional Sources for 18MF ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

18MF ETF Overview

Market Cap in USD 589m
Category Trading - Leveraged/Inverse Equity
TER 0.35%
IPO / Inception 2009-06-16

18MF ETF Ratings

Growth Rating 67.2
Fundamental -
Dividend Rating 0.0
Rel. Strength -22.5
Analysts -
Fair Price Momentum 20.16 EUR
Fair Price DCF -

18MF Dividends

Currently no dividends paid

18MF Growth Ratios

Growth Correlation 3m 74.7%
Growth Correlation 12m -0.8%
Growth Correlation 5y 84.5%
CAGR 5y 24.02%
CAGR/Max DD 5y 0.56
Sharpe Ratio 12m 0.28
Alpha -16.38
Beta 1.600
Volatility 20.12%
Current Volume 66.2k
Average Volume 20d 80.9k
Stop Loss 20.6 (-3.7%)
What is the price of 18MF shares?
As of July 12, 2025, the stock is trading at EUR 21.39 with a total of 66,247 shares traded.
Over the past week, the price has changed by +1.42%, over one month by +4.29%, over three months by +30.89% and over the past year by +2.42%.
Is Amundi Leveraged MSCI USA a good stock to buy?
Yes. Based on ValueRay's Analyses, Amundi Leveraged MSCI USA (XETRA:18MF) is currently (July 2025) a good stock to buy. It has a ValueRay Growth Rating of 67.16 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of 18MF is around 20.16 EUR . This means that 18MF is currently overvalued and has a potential downside of -5.75%.
Is 18MF a buy, sell or hold?
Amundi Leveraged MSCI USA has no consensus analysts rating.
What are the forecasts for 18MF share price target?
According to our own proprietary Forecast Model, 18MF Amundi Leveraged MSCI USA will be worth about 24.2 in July 2026. The stock is currently trading at 21.39. This means that the stock has a potential upside of +13.09%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 24.2 13.1%